Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
(Thomson Reuters ONE) -
Novartis International AG /
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only
water gradient lenses designed for people with presbyopia
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* Presbyopia is an eye condition that is part of natural aging affecting
nearly 2 billion people worldwide.[1]
* Dailies Total1® Multifocal contact lenses provide a seamless visual
experience offering an alternative to bifocals or reading glasses.
* They are designed to uniquely address end-of-day dryness and discomfort many
contact lens wearers experience after age 40.[4]-[10]
Basel, July 14, 2016 - Alcon, the global leader in eye care and a division of
Novartis, introduces Dailies Total1 Multifocal contact lenses for people with
presbyopia. This innovative multifocal lens provides both seamless distant,
intermediate and near vision, and the outstanding comfort of the Dailies Total1
water gradient lens technology.[1],[4]-[6] Dailies Total1 Multifocal contact
lenses use Alcon's Precision Profile(TM) lens design, a design also included in
Alcon's Air Optix® Aqua and Dailies Aqual Comfort Plus® multifocal contact
lenses.
Presbyopia is an eye condition that is part of natural aging that generally
begins after age 40.[1] It is the gradual decline of the eye's ability to focus
on nearby objects, causing them to appear blurry and out of focus. Presbyopia
affects nearly 2 billion people worldwide. Many contact lens wearers discontinue
the use of contact lenses after age 40 due to dryness, discomfort and visual
acuity issues.[2]-[3]
"Presbyopia can have a significant impact on people's quality of life as they
get older", said Mike Ball, CEO, Alcon. "With Dailies Total1 Multifocal, Alcon
has designed a unique contact lens that answers to the increased need for
comfort and the expectation of a seamless visual experience of people with
presbyopia."
The Dailies Total1 water gradient technology reduces end-of-day dryness, [4],[5]
as the water content approaches nearly 100% at the outermost surface of the
lens.[5],[6] The "hydrophilic" (water-loving) surface of the lens is almost as
soft as the surface of the cornea (corneal epithelium) to enhance
comfort,[6],[11]-[12] while the innovative optical design of this new multifocal
lens offers a smooth progression of power designed to provide a seamless
experience between distant, intermediate and near vision[13].
Dailies Total1 Multifocal contact lenses are commercially available in
Australia, Canada, United States and Switzerland as of July 27 and are expected
to be available in various EU countries by September 1.
About Dailies Total1(® )Multifocal Contact Lenses
Dailies Total1(®) Multifocal contact lenses are designed for people with
presbyopia and are intended to be used on a daily disposable basis. The contact
lenses are available with a power range of - 6.00 to + 3.00D and three ADD
powers (Low, Med, High). In most markets, Dailies Total1 Multifocal contact
lenses are medical devices that must be prescribed by an eye care professional.
See product instructions for complete wear, care, and safety information.
About Presbyopia
Much like adjusting the focus on a camera, the natural lens within the eye of
people under 40 years of age changes shape to properly focus on objects at
different distances. As the eye ages, it loses its ability to adjust, resulting
in diminished up-close vision. Presbyopia develops gradually, with most people
developing symptoms by their early to mid-40s. The most common symptoms of
presbyopia are blurred vision at normal reading distance, including while
wearing normal glasses or contact lenses, headaches, eyestrain and fatigue while
reading or doing close-up work. Nearly everyone experiences presbyopia;
scientists believe this to be a natural part of aging that cannot be prevented;
however, there are many treatment options for presbyopia including bifocals,
reading glasses, and multifocal contact lenses.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "launches," "introduces," "expected," or similar terms, or by
express or implied discussions regarding potential marketing approvals for
Dailies Total1 Multifocal contact lenses, or regarding potential future revenues
from Dailies Total1 Multifocal contact lenses, Air Optix Aqua Multifocal contact
lenses, Dailies AquaComfort Plus Multifocal contact lenses, and the other
products in Alcon's multifocal contact lens portfolio. You should not place
undue reliance on these statements. Such forward-looking statements are based on
the current beliefs and expectations of management regarding future events, and
are subject to significant known and unknown risks and uncertainties. Should one
or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary materially from those set
forth in the forward-looking statements. There can be no guarantee that Dailies
Total1 Multifocal contact lenses or any of the other products in Alcon's
multifocal contact lens portfolio will be submitted or approved for sale in any
additional markets, or at any particular time. Neither can there be any
guarantee that Dailies Total1 Multifocal contact lenses or any of the other
products in Alcon's multifocal contact lens portfolio will be submitted or
approved for any additional indications or labeling in any market, or at any
particular time. Nor can there be any guarantee that Dailies Total1 Multifocal
contact lenses or any of the other products in Alcon's multifocal contact lens
portfolio will be commercially successful in the future. In particular,
management's expectations regarding Dailies Total1 Multifocal contact lenses and
the other products in Alcon's multifocal contact lens portfolio could be
affected by, among other things, the uncertainties inherent in research and
development, including unexpected clinical trial results and additional analysis
of existing clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; unexpected safety, quality or manufacturing issues, and other risks
and factors referred to in Novartis AG's current Form 20-F on file with the US
Securities and Exchange Commission. Novartis is providing the information in
this press release as of this date and does not undertake any obligation to
update any forward-looking statements contained in this press release as a
result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
For Novartis multimedia content, please visit www.novartis.com/news/media-
library. For questions about the site or required registration, please contact:
media.relations(at)novartis.com
References
[1] Market Scope, Global Presbyopia-Correcting Surgery Market Report, April 2012
[2] Alcon data on file, 2013.
[3] Alcon data on file, 2015.
[4] Pérez-Gómez I, Giles T. European survey of contact lens wearers and eye care
professionals on satisfaction with a new water gradient daily disposable contact
lens. Clin Optom. 2014;6:17-23.
[5] Alcon data on file 2015.
[6] Dunn A, Uruena J, Huo Y, et al. Lubricity of surface hydrogel layers. Tribol
Lett. 2013;49:371-378.
[7] Thekveli S, Qui Y, Kapoor Y, Liang W, Pruitt J. Structure-property
relationship of delefilcon A lenses. Cont Lens Anterior Eye.
2012;35(Suppl 1):e14.
[8] Pruitt J, Qiu Y, Thekveli S, Hart R. Surface characterization of a water
gradient silicone hydrogel contact lens (delefilcon A). Invest Ophthalmol Vis
Sci. 2012;53:E-Abstract 6107.
[9] Alcon data on file, 2012.
[10] Alcon data on file, 2010.
[11] Angelini T, Nixon R, Dunn A, et al. Viscoelasticity and mesh size at the
surface of hydrogels characterized with microrheology. Invest Ophthalmol Vis
Sci. 2013;54:E-Abstract 500.
[12] Alcon data on file, 2013.
[13] Alcon data on file, 2016.
[14] http://myeyes.com/presbyopia/what-is-presbyopia.shtml
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Elizabeth Harness
Novartis Global Media Relations Alcon Communications
+41 61 324 7999 (direct) +1 817 551 8696 (direct)
+41 79 593 4202 (mobile) +1 585 435 7379 (mobile)
Eric.Althoff(at)novartis.com Elizabeth.Harness(at)alcon.com
e-mail: media.relations(at)novartis.com
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF):
http://hugin.info/134323/R/2028505/754126.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#2028505]
Unternehmensinformation / Kurzprofil:
Datum: 14.07.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 483262
Anzahl Zeichen: 12099
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 364 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
